These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38822731)
1. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease. Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL Expert Opin Emerg Drugs; 2024 Sep; 29(3):289-303. PubMed ID: 38822731 [TBL] [Abstract][Full Text] [Related]
2. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682 [TBL] [Abstract][Full Text] [Related]
3. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F F1000Res; 2020; 9():. PubMed ID: 32695312 [TBL] [Abstract][Full Text] [Related]
4. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. Creese B; Da Silva MV; Johar I; Ballard C Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230 [TBL] [Abstract][Full Text] [Related]
5. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study. Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849 [TBL] [Abstract][Full Text] [Related]
6. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Kirbach S; Simpson K; Nietert PJ; Mintzer J Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715 [TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease. Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087 [TBL] [Abstract][Full Text] [Related]
8. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727 [TBL] [Abstract][Full Text] [Related]
9. An update on the advancements in the treatment of agitation in Alzheimer's disease. Porsteinsson AP; Antonsdottir IM Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462 [TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Daiello LA Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594 [TBL] [Abstract][Full Text] [Related]
11. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337 [TBL] [Abstract][Full Text] [Related]
12. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation. Oguma T; Jino K Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937 [TBL] [Abstract][Full Text] [Related]
13. Antidepressants for agitation and psychosis in dementia. Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305 [TBL] [Abstract][Full Text] [Related]
14. Advancements in the treatment of agitation in Alzheimer's disease. Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445 [TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease. Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP J Am Med Dir Assoc; 2024 Oct; 25(10):105173. PubMed ID: 39053890 [TBL] [Abstract][Full Text] [Related]
16. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS; Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523 [TBL] [Abstract][Full Text] [Related]
17. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Ballard C; Waite J Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003476. PubMed ID: 16437455 [TBL] [Abstract][Full Text] [Related]
18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506 [TBL] [Abstract][Full Text] [Related]
19. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study. Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181 [TBL] [Abstract][Full Text] [Related]
20. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Kales HC; Lyketsos CG; Miller EM; Ballard C Int Psychogeriatr; 2019 Jan; 31(1):83-90. PubMed ID: 30068400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]